Adjunctive therapies are important, particularly where clotting factor concentrates are limited or not available, and may lessen the amount of treatment product required. First aid measures: In addition to increasing factor level with clotting factor concentrates
(or desmopressin in mild hemophilia A), protection (splint), rest, ice, compression, and elevation (PRICE) may be used as adjunctive management for bleeding in muscles and joints. Physiotherapy/rehabilitation is particularly important for functional improvement and recovery after musculoskeletal bleeds and for those with established hemophilic arthropathy (see ‘Principles of Physiotherapy/Physical Medicine in Hemophilia’). Antifibrinolytic drugs (e.g., tranexamic acid, epsilon aminocaproic acid) are effective as adjunctive treatment for mucosal bleeds and dental extractions (see ‘Tranexamic Acid’ and ‘Aminocaproic Acid’). Certain COX-2 inhibitors may be used judiciously Ibrutinib manufacturer for joint inflammation after an acute bleed and in chronic arthritis (see ‘Pain Management’). Prophylaxis is the treatment
by intravenous injection of factor concentrate to prevent anticipated bleeding (Table 1–4). Prophylaxis was conceived from the observation that moderate hemophilia patients with clotting factor level > 1 IU dL−1 seldom experience spontaneous bleeding and have much better preservation of joint function. [21-24] Prophylaxis prevents bleeding and joint destruction and should be the goal of therapy to preserve normal musculoskeletal function. (Level 2) [ [25-30] ] Prophylactic replacement ADAMTS5 of clotting
factor Tanespimycin solubility dmso has been shown to be useful even when factor levels are not maintained above 1 IU dL−1 at all times [27, 30, 31]. It is unclear whether all patients should remain on prophylaxis indefinitely as they transition into adulthood. Although some data suggest that a proportion of young adults can do well off prophylaxis [21, 31], more studies are needed before a clear recommendation can be made. [32] In patients with repeated bleeding, particularly into target joints, short-term prophylaxis for 4–8 weeks can be used to interrupt the bleeding cycle. This may be combined with intensive physiotherapy or synoviorthesis. (Level 3) [ [33, 34] ] Prophylaxis does not reverse established joint damage; however, it decreases frequency of bleeding and may slow progression of joint disease and improve quality of life. Prophylaxis as currently practiced in countries where there are no significant resource constraints is an expensive treatment and is only possible if significant resources are allocated to hemophilia care. However, it is cost-effective in the long-term because it eliminates the high cost associated with subsequent management of damaged joints and improves quality of life. In countries with significant resource constraints, lower doses of prophylaxis given more frequently may be an effective option.